← All trials
NCT06797336
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 19, 2024
- Primary completion
- Dec 15, 2026
- Completion date
- Jun 16, 2027
- First posted
- Jan 28, 2025
- Last posted
- Apr 2, 2025
- Enrollment
- 115
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PAQ Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.